EGFR and lung adenocarcinoma: Meanwhile, Jiang et al. also report a patient with lung adenocarcinoma harboring EGFR ex20ins who achieved disease control after receiving high-dose furmonertinib (160–240 mg daily, Table 2) (Jiang et al., 2022).